← All Entrada Therapeutics, INC filings

Entrada Therapeutics, INC DEF 14A proxy statements

Proxy statements, covering the matters put to shareholders at the annual meeting — board elections, auditor ratification and executive pay.

NASDAQ
TRDA
Entrada Therapeutics, INC
DEF: Entrada Therapeutics Sets 2026 Annual Meeting Date
Entrada Therapeutics announces its 2026 Annual Meeting of Stockholders, scheduled for June 10, 2026, to elect directors and ratify auditor appointment.
NASDAQ
TRDA
Entrada Therapeutics, INC
DEFA14A: Entrada Therapeutics Bolsters Board with Appointment of Biopharma Veteran Dr. Maha Radhakrishnan
Entrada Therapeutics, Inc. announced the expansion of its Board of Directors and the appointment of Dr. Maha Radhakrishnan, a seasoned biopharmaceutical executive, effective June 1, 2025.
NASDAQ
TRDA
Entrada Therapeutics, INC
DEFA14A: Entrada Therapeutics, Inc. Sets Date for 2025 Annual Meeting
Entrada Therapeutics, Inc. will hold its 2025 Annual Meeting online on June 11, 2025, with voting open until June 10, 2025.
NASDAQ
TRDA
Entrada Therapeutics, INC
DEF: Entrada Therapeutics Sets Date for 2025 Annual Stockholders Meeting
Entrada Therapeutics will hold its 2025 Annual Meeting of Stockholders virtually on June 11, 2025, to elect directors and ratify the appointment of its accounting firm.
NASDAQ
TRDA
Entrada Therapeutics, INC
DEFA14A: Entrada Therapeutics Sets Date for 2024 Annual Meeting, Outlines Key Proposals
Entrada Therapeutics will hold its 2024 Annual Meeting online on June 13, 2024, featuring proposals for director election, auditor ratification, and liability limitation for officers.
NASDAQ
TRDA
Entrada Therapeutics, INC
DEF 14A: Entrada Therapeutics Sets Date for 2024 Annual Stockholders Meeting, Proposes Officer Liability Amendment
Entrada Therapeutics will hold its 2024 Annual Meeting of Stockholders virtually on June 13, 2024, to vote on director election, auditor ratification, and an amendment to limit officer liability.